<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871035</url>
  </required_header>
  <id_info>
    <org_study_id>IPET-GBS 1.2</org_study_id>
    <nct_id>NCT04871035</nct_id>
  </id_info>
  <brief_title>Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)</brief_title>
  <acronym>IPET-GBS</acronym>
  <official_title>Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DiaMed GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observations study evaluating safety and efficacy of immunoadsorption compared to&#xD;
      plasma exchange in Guillain-Barré Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">May 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 4, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Score</measure>
    <time_frame>2 weeks</time_frame>
    <description>Combined score consisting of Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, Oxford muscle strength score, and vibration score, equally weighted</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Neuropathy Cause and Treatment (INCAT) disability score</measure>
    <time_frame>2 weeks</time_frame>
    <description>Standard clinical score for inflammatory neuropathies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxford Muscle Strength Score (Medical Research Council, MRC)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Standard clinical score for evaluating muscle strength / paresis. Muscle strength will be measured on a scale between 0 (no movement) and 5 (full strength) on 8 pre-defined muscles (one proximal and one distal muscle at each extremity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vibration Score</measure>
    <time_frame>2 weeks</time_frame>
    <description>Standard clinical score for evaluation of vibration sensitivity on a scale between 0 and 8, using a 256 tuning fork at 4 predefined spots (processus styloideus radii and malleolus lateralis on both sides).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Score</measure>
    <time_frame>1, 3, and 5 weeks</time_frame>
    <description>Combined score consisting of Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, Oxford muscle strength score, and vibration score, equally weighted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Neuropathy Cause and Treatment (INCAT) disability score</measure>
    <time_frame>1, 3, and 5 weeks</time_frame>
    <description>Standard clinical score for inflammatory neuropathies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford Muscle Strength Score (Medical Research Council, MRC)</measure>
    <time_frame>1, 3, and 5 weeks</time_frame>
    <description>Standard clinical score for evaluating muscle strength / paresis. Muscle strength will be measured on a scale between 0 (no movement) and 5 (full strength) on 8 pre-defined muscles (one proximal and one distal muscle at each extremity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vibration Score</measure>
    <time_frame>1, 3, and 5 weeks</time_frame>
    <description>Standard clinical score for evaluation of vibration sensitivity on a scale between 0 and 8, using a 256 tuning fork at 4 predefined spots (processus styloideus radii and malleolus lateralis on both sides).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hughes Score</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Standard clinical score to quantify disability in Guillain-Barré syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Pain quantified on a visual analog scale between 0 (no pain) and 10 (maximum pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N20</measure>
    <time_frame>2 and 5 weeks</time_frame>
    <description>N20 latency of nervus medianus (both sides) as measured by somatosensory evoked potentials (SEPs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P40</measure>
    <time_frame>2 and 5 weeks</time_frame>
    <description>P40 latency of nervus tibialis (both sides) as measured by somatosensory evoked potentials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nerve Conduction Velocity</measure>
    <time_frame>2 and 5 weeks</time_frame>
    <description>Nerve conduction velocity of clinically affected nerves as measured by electroneurography (ENG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life 5 Dimensions 5 Levels (EQ-5D-5L)</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Quality of Life Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin A in serum</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Immunoglobulin A serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin A in cerebrospinal fluid (CSF)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Immunoglobulin A concentration in cerebrospinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G in serum</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Immunoglobulin G serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G in cerebrospinal fluid (CSF)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Immunoglobulin G concentration in cerebrospinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin M in serum</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Immunoglobulin M serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin M in cerebrospinal fluid (CSF)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Immunoglobulin M concentration in cerebrospinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-1</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Interleukin-1 serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Interleukin-6 serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-GM1 antibodies</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Anti-GM1 antibody serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-GQ1b</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Anti-GQQ1b antibody serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurofilament light chain (NfL) serum</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Neurofilament light chain (NfL) serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurofilament light chain (NfL) in cerebrospinal fluid (CSF)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Neurofilament light chain (NfL) levels in cerebrospinal fluid (CSF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Kind and frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Response</measure>
    <time_frame>1, 2, 3, and 5 weeks</time_frame>
    <description>Share of patients with at least 20% improvement in CIDP score</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>GBS</condition>
  <arm_group>
    <arm_group_label>Immunoadsorption</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasma Exchange</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Immunoadsorption</intervention_name>
    <description>1 cycle, consisting of 5 sessions on 5 consecutive days with processing of the 0.7-fold individual plasma volume (maximum 2.5 l) each days with tryptophan adsorbers.</description>
    <arm_group_label>Immunoadsorption</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Plasma Exchange</intervention_name>
    <description>1 cycle, consisting of 5 sessions on 5 consecutive days with exchange of 0.7-fold plasma volume (maximum 2.5 l) each day with albumin solution as volume replacement solution.</description>
    <arm_group_label>Plasma Exchange</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of patients diagnosed with Guillain-Barré syndrome (GBS) who&#xD;
        are treated with either plasma exchange or immunoadsorption in the Department of Neurology,&#xD;
        University of Ulm.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Guillain-Barré Syndrome according to the diagnostic criteria proposed by&#xD;
             Doorn et al. (Clinical features, pathogenesis, and treatment of Guillain-Barré&#xD;
             syndrome, Lancet neurology 2008)&#xD;
&#xD;
          -  age 18 years or above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical or laboratory (C-reactive protein 20 mg/l or above, or evidence of&#xD;
             nitrite-positive urinary tract infection) evidence of manifest systemic infection&#xD;
&#xD;
          -  Intake of angiotensin converting enzyme inhibitor within1 weeks before first treatment&#xD;
&#xD;
          -  Other contraindications against immunoadsorption or plasma exchange&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Dorst, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Dorst, Prof</last_name>
    <phone>+49 731 177 5285</phone>
    <email>johannes.dorst@uni-ulm.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert C Ludolph, MD, Prof.</last_name>
      <phone>+49-731-177-</phone>
      <phone_ext>1200</phone_ext>
      <email>albert.ludolph@rku.de</email>
    </contact>
    <investigator>
      <last_name>Albert C Ludolph, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Albert Christian Ludolph, Prof.</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guillain-Barre Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after de-identification (text, tables, and figures), as well as the study protocol will be available. Data will be available beginning 3 months and ending 5 years following article publication. Data will be shared with researchers who provide a methodologically sound proposal. Data will be shared for analyses to achieve the aims in the approved proposal. Proposals should be directed to johannes.dorst@uni-ulm.de; to gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at https://www.uniklinik-ulm.de/neurologie.html.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>3 months after publication until 5 years after publication</ipd_time_frame>
    <ipd_access_criteria>Data will be shared with researchers who provide a methodologically sound proposal. Data will be shared for analyses to achieve the aims in the approved proposal.</ipd_access_criteria>
    <ipd_url>https://www.uniklinik-ulm.de/neurologie.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

